Magenta Therapeutics, Inc.
MGTANASDAQHealthcare
$0.70
$-0.06(-7.74%)
Market Cap$42441024
P/E Ratio—
52W High$1.81
52W Low$0.321
Magenta Therapeutics, Inc. (MGTA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MGTA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.04M | $6.24M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 0.00% | 0.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $145.64M | $83.11M | $55.14M | $46.77M | $50.62M |
| G&A Expenses | $34.33M | $24.99M | $25.76M | $27.93M | $28.09M |
| Total Operating Expenses | $179.97M | $108.10M | $80.90M | $74.69M | $78.70M |
| Operating Income | ($177.93M) | ($101.86M) | ($80.90M) | ($74.69M) | ($78.70M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $16.12M | $17.36M | $0.00M | $3.56M | $3.77M |
| Interest Expense | $0.00M | $0.00M | ($4.44M) | $0.00M | $0.00M |
| Income Before Tax | ($162.34M) | ($84.97M) | ($76.46M) | ($71.14M) | ($74.94M) |
| Income Tax Expense | $0.00M | $0.00M | ($4.44M) | ($5.58M) | ($5.74M) |
| Net Income | ($162.34M) | ($84.97M) | ($72.02M) | ($65.56M) | ($69.19M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-21.75 | $-23.05 | $-1.12 | $-1.43 |
| Wtd Avg Shares | 0.00M | 3.91M | 3.12M | 58.79M | 48.46M |
| EBITDA | ($177.93M) | ($101.86M) | ($78.98M) | ($74.69M) | ($78.70M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Magenta Therapeutics, Inc. data
About Magenta Therapeutics, Inc. (MGTA) Income Statement
Magenta Therapeutics, Inc. (MGTA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MGTA reported revenue of $0.00B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.16B) — a net profit margin of -7973.33%.
Frequently asked questions
MGTA · 4 questionsMagenta Therapeutics, Inc. (MGTA) reported revenue of $0.00B for 2025, down 67.3% year-over-year.
MGTA revenueMGTA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09